Development of a molecular genetic diagnostic service for X-linked ichthyosis, with emphasis on carrier detection Eleanor Reavey West of Scotland Regional.

Slides:



Advertisements
Similar presentations
Linkage and Genetic Mapping
Advertisements

CF Case Studies Frances Bond West Midlands Regional Genetics Laboratory 15/10/08 SCOBEC & Birmingham Case Studies Training Day.
Familial adenomatous polyposis
A friendly clinician has asked you to go about setting up a test for a genetic disorder previously characterised by a research laboratory. Discuss how.
HNPCC Case report Referral Bowel Cancer aged 49 and a possible family History of HNPCC.
Clinical background: Patient RM, YoB 1966 Her family were originally referred because of a history of breast and ovarian cancer. BRCA testing found a missense.
Suggestions for PMS2 best practice Jenny Simmonds
High School Version.  In 1904, a student from the West Indies came to a Chicago physician, Dr. James Herrick, with a puzzling condition. Below is a summary.
Genetics and inheritance Questions with true or false answers
TYPES OF MUTATION CAUSING HUMAN GENETIC DISEASE Nucleotide substitutions (point mutations) Missense mutations Nonsense mutations Spice site mutations Frame.
Auditing antenatal diagnoses – what is good practice? Sarah Ball, Tim Hutchin, George Gray, Linda Jenkinson, Mary Anne Preece West Midlands Laboratory.
Assessment of a high-throughput DNA melting analysis assay for rapid screening of gene variants in the ornithine transcarbamylase gene K. Sumner*, L. Hubley*,
POSITIONAL CLONING TWO EXAMPLES. Inheritance pattern - dominant autosomal Entirely penetrant and fatal Frequency - about 1/10,000 live births Late onset.
The Genetics of Breast and Ovarian Cancer Susceptibility Patricia Tonin, PhD Associate Professor Depts. Medicine, Human Genetics & Oncology McGill University.
DNA marker analysis Mrs. Stewart Medical Interventions Central Magnet School.
Issues in Genetic Testing: Real versus Not-so-Real Roberta A Pagon, MD Principal Investigator, GeneTests Professor, Pediatrics University of Washington.
Chris Campbell West Midlands Regional Genetics laboratory
Prenatal diagnosis Dr Neda Bogari.
Clinical Applications of Genetic Tests Mikenzie Lewis.
What is Genetic Testing? And what is its value? Sherri J. Bale, Ph.D., FACMG President and Clinical Director GeneDx.
Pregnancy & Newborn Screening Developments
Genetic Testing for Wilson Disease Melissa Dempsey, M.S., CGC The University of Chicago Genetic Services Laboratory July 17, 2010.
Breast Screening. NHS Breast Screening Programme Introduced in 1988 Invites women from age group for screening every 3 yrs. Age extension roll-out.
Affymetrix Resequencing Arrays Matthew Smith Trainee Presentation West Midlands Regional Genetics Laboratory.
Duchenne Muscular Dystrophy: The Diagnostic Process.
The Genetics of Ichthyosis Sherri J. Bale, PhD, FACMG Clinical Director, GeneDx FIRST Family Conference Orlando, FL - June 27, 2010.
Genetic Testing. What is Genetic Testing? Analysis of human DNA, chromosomes and/or proteins Analysis of human DNA, chromosomes and/or proteins Used to:
Caroline O.A. Melo, Daniela M. Silva, and Aparecido D. da Cruz
Proof of Principle for the Non-Invasive Prenatal Diagnosis of Fetal Trisomy 21 Sarah Fielding NE Thames Regional Genetics Service.
Expanded PLA2G6 Copy Number Variant Analysis in Patients with Infantile Neuroaxonal Dystrophy (INAD) Danielle Crompton, P. K. Rehal, L. MacPherson, K.
Investigating the use of Multiple Displacement Amplification (MDA) to amplify nanogram quantities of DNA to use for downstream mutation screening by sequencing.
Introduction Sandeepa Chauhan, Madhumita Roy Chowdhury, Neerja Gupta, Sheffali Gulati*, BK Thelma #, Anjali Dabral #, Madhulika Kabra Genetic Unit, Department.
Implementation of a new diagnostic service for congenital adrenal hyperplasia Charlene Crosby West Midlands Regional Genetics Laboratory.
From the Gene to the Genome Genetic Inheritance Patterns Observing Genetic Differences in the DNA.
Hemophilia Research Center for Genetic Engineering and Biotechnology “Georgi D. Efremov”, MASA What is: Hemophilia is an X-linked congenital bleeding disorder.
Apparent homozygous deletion identified in Alström syndrome patient Elizabeth Perrott West Midlands Regional Genetics Laboratory.
Jonathan Callaway Wessex Regional Genetics Laboratory
A Diagnostic Testing Service for Hypophosphatemic Rickets
Problem 1 James is the only person in his kindred affected by DMD. He has one unaffected brother, Joe. DNA analysis show that James has a deletion in the.
Using a Single Nucleotide Polymorphism to Predict Bitter Tasting Ability Lab Overview.
Understanding Genetic Testing
The Genetics of Ichthyosis
4.3 Alterations In Chromosome Structure and Number
© 2013 Pearson Education, Inc. Extensions of Mendelian Genetics  Incomplete Dominance is when a heterozygote expresses a phenotype intermediate between.
Gene350 Animal Genetics Lecture 5 3 August Last Time Study chromosomes – The normal karyotypes of animals – Chromosomal abnormalities – Chromosomal.
MCADD, caused by mutation in the ACADM gene is the most common disorder of fatty acid  - oxidation. Treatment is very successfully if started before symptoms.
Mutational Spectrum in Egyptian CAH Patients
How Can You Study Human Heredity?
Development of a next-generation sequencing gene panel for neurogenetic disorders J E Martindale, R Crookes, L Crooks, N J Beauchamp, A Dalton Sheffield.
Frances Bond West Midlands Regional Genetics Laboratory 12/04/10
Characterization of VHL promoter variants in patients suspected of Von Hippel Lindau Saleh Albanyan, Rachel Giles, Raymond H Kim, MD/PhD Division of.
Molecular Approaches for Screening of Genetic Diseases
Diagnostic Testing for Rett Syndrome by DHPLC and Direct Sequencing Analysis of the MECP2 Gene: Identification of Several Novel Mutations and Polymorphisms 
Genetic Testing Result Means. Before Genetic Testing  The result of genetic testing can be life changing.  It is important for patients and their families.
Patient VB Li-Fraumeni Syndrome.
Peter John M.Phil, PhD Atta-ur-Rahman School of Applied Biosciences (ASAB) National University of Sciences & Technology (NUST)
STEVE S. SOMMER, M.D., Ph.D.  Mayo Clinic Proceedings 
Fragile X Syndrome The Journal of Molecular Diagnostics
Thomas W. Prior, Scott J. Bridgeman 
Analysis of Rare APC Variants at the mRNA Level
Validation and Clinical Application of a Locus-Specific Polymerase Chain Reaction- and Minisequencing-Based Assay for Congenital Adrenal Hyperplasia (21-Hydroxylase.
Comprehensive Mutation Analysis of the CYP21A2 Gene
Survival of Male Patients with Incontinentia Pigmenti Carrying a Lethal Mutation Can Be Explained by Somatic Mosaicism or Klinefelter Syndrome    The.
Imprinting at the SMPD1 Locus: Implications for Acid Sphingomyelinase–Deficient Niemann-Pick Disease  Calogera M. Simonaro, Jae-Ho Park, Efrat Eliyahu,
The Content of the Genome
Volume 58, Issue 2, Pages (August 2000)
Key Area 2.4 – Ante- and Post-natal Screening
The MLPA assay and application to diagnosis of DGS
Exon Skipping in IVD RNA Processing in Isovaleric Acidemia Caused by Point Mutations in the Coding Region of the IVD Gene  Jerry Vockley, Peter K. Rogan,
Presentation transcript:

Development of a molecular genetic diagnostic service for X-linked ichthyosis, with emphasis on carrier detection Eleanor Reavey West of Scotland Regional Genetics Laboratory Yorkhill Hospital Glasgow Glasgow

Introduction Associated with STS deficiency in fibroblasts and ↑ plasma cholesterol sulphate Associated with STS deficiency in fibroblasts and ↑ plasma cholesterol sulphate X-linked recessive inheritance X-linked recessive inheritance 1 in males 1 in males STS gene - Xp22.3 STS gene - Xp exons 10 exons

STS enzyme STS enzyme Responsible for hydrolysis of cholesterol sulfate (CS) to cholesterol in epidermis Responsible for hydrolysis of cholesterol sulfate (CS) to cholesterol in epidermis XLI – accumulation of CS in epidermis leads to barrier instability and inhibits desmosomal degradation XLI – accumulation of CS in epidermis leads to barrier instability and inhibits desmosomal degradation Phenotype Phenotype Scaly skin on scalp, trunk and limbs Scaly skin on scalp, trunk and limbs Corneal opacities Corneal opacities

Placental sulphatase deficiency Placenta – STS-rich tissue Placenta – STS-rich tissue STS is involved in steroid conversion pathway: cholesterol  estriol STS is involved in steroid conversion pathway: cholesterol  estriol Deficiency associated with: Deficiency associated with: longer gestation and poor cervical dilatation longer gestation and poor cervical dilatation Results in slowing of delivery + indicates need for C-section or instrumental delivery Results in slowing of delivery + indicates need for C-section or instrumental delivery ↑ perinatal morbidity + mortality ↑ perinatal morbidity + mortality

Associated Conditions Approx. 90% of XLI individuals – complete deletion of the STS gene Approx. 90% of XLI individuals – complete deletion of the STS gene More extensive deletions - contiguous gene deletion syndromes More extensive deletions - contiguous gene deletion syndromes Kallmann syndrome Kallmann syndrome Short stature Short stature X-linked chondrodysplasia punctata X-linked chondrodysplasia punctata X-linked ocular albinism X-linked ocular albinism ADHD ADHD

Biochemical Analysis STS activity is measured on white cells or cultured fibroblasts STS activity is measured on white cells or cultured fibroblasts Radiolabelled assay with 3H Dehydroepiandrosterone sulphate as a substrate Radiolabelled assay with 3H Dehydroepiandrosterone sulphate as a substrate Affected males are tested for presence or absence of STS gene by PCR Affected males are tested for presence or absence of STS gene by PCR No info on any intragenic deletions or point mutations No info on any intragenic deletions or point mutations

Mutations Several point mutations in STS gene identified Several point mutations in STS gene identified No evidence of genotype-phenotype correlation, regardless of the location or type of the STS mutation No evidence of genotype-phenotype correlation, regardless of the location or type of the STS mutation production of a catalytically inactive STS enzyme production of a catalytically inactive STS enzyme both the N-terminal region and the C-terminal region of the STS protein are important for enzyme activity both the N-terminal region and the C-terminal region of the STS protein are important for enzyme activity

Initial referral Patient NH clinically affected with XLI Patient NH clinically affected with XLI No enzyme activity detected No enzyme activity detected But, normal result for gene deletion analysis But, normal result for gene deletion analysis Request from Dundee for full seq screen of STS coding exons (1-10), including intron/exon boundaries Request from Dundee for full seq screen of STS coding exons (1-10), including intron/exon boundaries Primers designed for sequencing Primers designed for sequencing

Y chr Pseudogene Transcriptionally inactive at the promoter Transcriptionally inactive at the promoter Several exons deleted Several exons deleted Significant sequence homology between X-STS and Y-STS genes Significant sequence homology between X-STS and Y-STS genes

Results from Temperature Gradient PCR 55°C - 65°C 55°C - 65°C Example gel for exons 1-8 Example gel for exons 1-8 Exon  C 58  C 60  C 62  C 65  C

NH c.583delG p.Val195SerfsX19

Further Testing Screening of NH’s mother confirmed her as a carrier. Screening of NH’s mother confirmed her as a carrier. Second referral – Edinburgh Second referral – Edinburgh Patient JM clinically affected, no STS activity and normal result on gene deletion analysis Patient JM clinically affected, no STS activity and normal result on gene deletion analysis

JM c.387_391dupAGCAC p.Leu131GlnfsX3

Extended Testing A further 10 samples were received from Dr Graham A further 10 samples were received from Dr Graham Dosage analysis carried out to confirm presence of STS gene Dosage analysis carried out to confirm presence of STS gene Full sequencing screen carried out on all 10 exons Full sequencing screen carried out on all 10 exons Four additional mutations detected = high pickup rate Four additional mutations detected = high pickup rate

STS dosage analysis DMD 53 STS 5’ DMD 17 STS 3’ DMD 51

MD c.1046_1048delAGG p.Glu349del

TT c.1649G>A p.Trp550X

AE c.1360C>T p.Arg454Cys

JA c.494C>T p.Thr165Ile

MLPA kit P160 Probes for each of 10 exons Probes for each of 10 exons Other probes include KAL1 and NLGN4X Other probes include KAL1 and NLGN4X In female heterozygotes, 35-50% reduced relative peak area of amplified product expected In female heterozygotes, 35-50% reduced relative peak area of amplified product expected Deletion of one exon – needs to be confirmed by sequencing to rule out mutation/ polymorphism close to probe ligation site Deletion of one exon – needs to be confirmed by sequencing to rule out mutation/ polymorphism close to probe ligation site

Carrier testing in females

Current testing strategy for XLI in Glasgow Enzyme activity measured and gene deletion PCR carried out in Biochemical Genetics Enzyme activity measured and gene deletion PCR carried out in Biochemical Genetics Dosage assay available in Molecular Genetics Lab to identify female carriers Dosage assay available in Molecular Genetics Lab to identify female carriers MLPA better suited for carrier testing – detects single (or multiple) exon deletions/ duplications as well as deletions of entire gene MLPA better suited for carrier testing – detects single (or multiple) exon deletions/ duplications as well as deletions of entire gene

Sample is received by Biochemical Genetics at Yorkhill Hospital for XLI diagnostic analysis Steroid sulphatase enzyme analysis carried out on white cells Report patient as negative for XLI -ve + ve Dosage analysis to identify partial/ full STS gene deletions + ve Report patient is affected with XLI due to a STS gene deletion Offer mother, and other family members, MLPA testing for carrier status -ve Full screen sequencing of 10 coding exons of STS gene to identify point mutations -ve Offer mother, and other family members, STS sequence testing for identified point mutation Confirm XLI diagnosed biochemically however, genetic basis is unknown

Summary Service offered for males affected with XLI – dosage analysis + full screen sequencing for point mutations Service offered for males affected with XLI – dosage analysis + full screen sequencing for point mutations Carrier testing for mothers Carrier testing for mothers Important for genetic counselling for future pregnancies and for predicting risk of difficult labour Important for genetic counselling for future pregnancies and for predicting risk of difficult labour

Acknowledgements Molecular Genetics Lab, Yorkhill, Glasgow Molecular Genetics Lab, Yorkhill, Glasgow Su Stenhouse, Sandy Cooke Su Stenhouse, Sandy Cooke Biochemical Genetics Lab, Yorkhill, Glasgow Biochemical Genetics Lab, Yorkhill, Glasgow Gordon Graham Gordon Graham